Chromosomal focal amplifications often cause an increase in gene copy number, contributing to the pathogenesis of cancer. PRR14 overexpression is associated with recurrent locus amplification in lung cancer, and it correlates with a poor prognosis. We show that increased PRR14 expression promoted and reduced PRR14 expression impeded lung cancer cell proliferation. Interestingly, PRR14 cells were markedly enlarged in size and exhibited an elevated activity of the PI3-kinase/Akt/mTOR pathway, which was associated with a heightened sensitivity to the inhibitors of PI3K and mammalian target of rapamycin (mTOR). Biochemical analysis revealed that PRR14, as a proline-rich protein, binds to the Src homology 3 (SH3) domains of GRB2 resulting in PI3K activation. Significantly, two cancer patient-derived PRR14 mutants displayed considerably augmented GRB2-binding and an enhanced ability of promoting cell proliferation. Together with the in vivo data demonstrating a strong tumor-promoting activity of PRR14 and the mutants, our work uncovered this proline-rich protein as a novel activator of the PI3K pathway that promoted tumorigenesis in lung cancer.
INTRODUCTION
Lung cancer is a leading cause of cancer-related deaths claiming lives of over 25% of cancer patients (26% in woman and 28% in man). 1 Basically, it is divided into two broad groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC, which accounts for~85% of lung cancers, can be further subtyped to lung squamous cell carcinoma (LUSC), adenocarcinoma (LUAD) and large cell carcinoma. The majority of NSCLC patients are diagnosed at an advanced stage, where chemotherapy may improve survival and palliation of symptoms, but has reached a plateau in efficacy with a median survival of 8-10 months, 2 raising a pressing need of identifying novel therapeutic targets.
A commonly activated pathway in NSCLC is the PI3K/AKT/ mammalian target of rapamycin (mTOR) pathway. 3 A broad range of cancer-related functions has been associated with this signaling pathway, including cell proliferation, 4 glucose transport and catabolism, 5 cell adhesion, 6 apoptosis, 7 RAS signaling 8 and oncogene transformation. [9] [10] [11] Several subunits of PI3Ks 12, 13 and their up or downstream effectors, including GRB2, 14, 15 have been found to be amplified or activated in human tumors. Indeed, mTOR phosphorylation increased with the malignant progression, and blocking mTOR was sufficient to block lung tumor progression. 16 We report in this study the role of the Proline-Rich Protein 14 (PRR14), an understudied gene located in the 16p11.2 region, which is recurrently increased in copy number and overexpressed in lung cancer. Using integrated approach consisting of genomics, in vitro and in vivo molecular studies, we estimated PRR14 oncogenic features in lung cancer. Our observations suggest that PRR14 is an oncogene that has an important role in lung cancers and is a first report linking PRR14 with carcinogenesis.
RESULTS

PRR14 is amplified and overexpressed in lung cancer
Studies using comparative genomic hybridization have revealed that the region 16p11.2, which contains PRR14, is recurrently increased in copy number in lung cancer. 17 Data mining from The Cancer Genome Atlas (TCGA) show consistent copy number increase in lung cancer (Figure 1a ), which correlates with significantly enhanced PRR14 transcription in both adenocarcinoma and squamous cell carcinoma (Figure 1b) . Because of the lack of SCLC data, we analyzed the gene expression data from Cancer Cell Line Encyclopedia and compared the PRR14 expression level in different cell lines from either SCLCs or NSCLCs ( Figure 1c ). There is no significant difference between cell lines from these two different types of lung cancer, suggesting that PRR14 expression is also increased in SCLCs. The high expression of PRR14 in lung cancer cases significantly associates with worse 5-year survival in all lung cancers (SCLC, LUSC and LUAD; P = 0.05), especially LUAD (P = 0.0043) and LUSC (P = 0.02; Figure 1d ).
Overexpression of PRR14 in cancer samples associates with increased gene expression The PRR14 mRNA level was significantly increased in lung cancer samples compared with healthy controls, and its expression levels varied across cancer samples. Therefore, we decided to explore what effect high-PRR14 expression has within cancer samples deposited in TCGA database. Using Gitools 2.2.2 18 LUAD and LUSC data sets, we extracted the high-PRR14 (40.5) and low-PRR14 expression samples (o − 0.5) and performed differential expression analysis across deposited transcriptome (Supplementary Figure 1) .
The comparative analysis of 42 high-PRR14-and 38 low-PRR14-expressing samples within TCGA-LUAD collection showed 714 differentially expressed (DE) transcripts (qo0.001) where 80% were overexpressed in high-PRR14 samples (Supplementary Table 1 ). The analysis in TCGA-LUSC collection performed on 31 low-PRR14-and 32 high-PRR14 samples showed 480 transcripts, where 71% was overexpressed in high-PRR14 samples (Supplementary Table 2 ). In both LUAD and LUSC collections we observed increased expression of transcripts in high-PRR14 samples, and it was more profound in LUAD collection compared with LUSC data set. The high-PRR14 expression level associated with increased gene expression in both LUAD and LUSC types of cancer. We compared the DE transcripts in both collections discovering 176 common DE transcripts, out of which 164 were increased with high-PRR14 expression levels (Figure 2a) . Further, we performed overrepresentation analysis of common and unique DE transcripts in LUAD and LUSC collections with ConsensusPathDB. 19 Using 176 commonly DE genes in both cancers (Figure 2 ), 11 pathways were statistically significantly over-represented (Figure 2b , Supplementary Table 3 ). Two top hit pathways were Gene Expression (qo0.0001) and Generic Transcription Pathways (q = 0.0024; Figure 2d ). The over-representation analysis performed on unique DE transcripts separately in LUSC and LUAD collections showed 46 in LUAD and 11 in LUSC over-represented pathways (Supplementary Table 3 ). Information derived from human TCGA data analysis suggests PRR14 as a potential lung cancer gene. PRR14 is positively associated with lung cancer cell proliferation We next went on functionally characterizing PRR14. As PRR14 expression is increased in lung cancer, we asked whether PRR14 might affect lung cancer cell proliferation. To test this hypothesis, we employed two NSCLC cell lines, H1299 and A549, and performed knockdown experiments. A mixture of three different short interfering RNAs (siRNAs) targeting three sites of PRR14 was used to decrease its expression. Quantitative real-time PCR (qRT-PCR) analysis showed that the PRR14 mRNA level was reduced to o50% by the siRNAs (Figures 3a and d) . In both NSCLC cell lines, decreased PRR14 expression resulted in slower proliferation rate (Figures 3b and e) and significantly lower colony formation capacity (Figures 3c   and f) . We additionally performed a rescue experiment to ensure there was no off-target effect (S3).
Consequently, we expected that the overexpression of PRR14 would increase the proliferation rate. We generated PRR14 overexpression stable cell line and its empty vector control cell line in H1299 through a retrovirus-mediated gene transfer. PRR14 overexpression was confirmed by immunoblot (Figure 3g) , and it correlated with higher proliferation rate (Figure 3h ) as well as significantly higher colony formation capacity (Figure 3i ). The ability of PRR14 to stimulate lung cancer cell proliferation was independently validated (Supplementary Figure 1B-D) . Altogether, these results indicate that PRR14 expression is critical for lung cancer cell proliferation in vitro. PRR14 activates the Akt/mTOR signaling pathway Interestingly, we noticed that the PRR14 overexpression cells are significantly larger in size than the control cells (Figure 4a ), which was confirmed with flow cytometry analysis ( Figure 4b ). As the mTOR signal pathway is known to regulate mammalian cell size, 20, 21 the enlarged cell volume and global gene overexpression prompted us to probe a potential involvement of the mTOR pathway. The immunoblot result indicated that PRR14 overexpression was associated with an elevated phosphorylation in both H1299 and A549 cell lines of PDK1, AKT, S6K, ERK and S6, consistent with an increased activity of the mTOR pathway (Figure 4c ). To complement the result derived from PRR14-overexpressing cells, we depleted PRR14 expression using siRNA. In contrast to the elevated protein phosphorylation in PRR14-overexpressing cells, PRR14 underexpression resulted in marked decrease in phosphorylation of PDK1 and the downstream markers (Figure 4d ), which was consistent with decreased cell proliferation. Alternatively, the highly conserved RAS family of GTPases (HRAS, NRAS and KRAS) is known for its involvement of oncogenesis, the regulation of cell size and is one of the common upstream stimulators of the Akt/mTOR pathway. 8, 21, 22 To further pinpoint the exact effective target of PRR14 in the PI3K/ Akt/mTOR signaling pathway, we measured Ras activity in H1299 stable cell lines ( Figure 4e ). As expected, serum starvation decreased Ras activity, which quickly recovered to original level upon serum replenishment. The PRR14-expressing cells displayed higher Ras activity under both serum-starved and -stimulated conditions ( Figure 4e , lanes 4-6), implicating a PRR14-mediated stimulation of Ras.
Furthermore, it was reported that the PI3K/Akt/mTOR signaling pathway-increased cell size is mediated through an increased protein synthesis rate. Therefore, the protein synthesis rate was monitored and compared between PRR14-overexpressing and its control cell lines ( Figure 4f ). As expected, protein translation inhibitor cycloheximide dramatically decreased protein synthesis. Increased PRR14 expression significantly increased the protein synthesis rate (P = 0.0394), which is consistent with activated the Gene Expression signal pathway in TCGA samples (Figure 2d ).
In addition, PRR14-mediated increased activity of the Akt/mTOR signaling pathway was completely blocked by either PI3K inhibitor GDC or mTOR inhibitor Torin2; however, mitogen-activated protein kinase inhibitor U0126 showed no effect on the activation (Figure 5a ). The data together suggest that PRR14 targeted Ras or its upstream to stimulate the activity of the PI3K/Akt/mTOR pathway.
We went on to test whether the PI3K/Akt/mTOR pathway was responsible for PRR14-induced cell proliferation. It has been shown that the PI3K inhibitor LY294002 alone rendered cells with highly activated Akt more sensitive to apoptosis and growth inhibition. 23 We assessed the contribution of PI3K/Akt/mTOR to PRR14-mediated cell proliferation by treating cells with 10 μM LY294002. The PRR14-overexpressing cells were considerably more sensitive to LY294002-induced inhibition of cell proliferation (Figure 5b ). To complement with the treatment with LY294002, we treated cells with two additional inhibitors, Torin2 (Figure 5c ) and U0126 (Figure 5d ). Consistently, PRR14 showed a heightened sensitivity to PI3K/Akt/mTOR signal pathway inhibitors, LY294002 and Torin2. Of note, the cells did not show significantly different sensitivity to U0126 treatment (Figure 5d ), indicative of an effect specific to the PI3K/Akt/mTOR signaling pathway. Correspondingly, PRR14-overexpressing cell line with an increased PI3K/Akt/ mTOR signaling pathway activity showed more resistance to Bleomycin, a DNA damage-inducing chemical (S2 A).
PRR14 stimulates the PI3K/Akt/mTOR pathway via interacting with GRB2 To explore how PRR14 activated Ras as well as PI3K, we focused on GRB2, a protein functioning upstream of both. [24] [25] [26] GRB2 is a docking protein containing an SH2 domain flanked by N-and C-terminal Src homology 3 (SH3) domains. 27 PRR14 on the other hand is a proline-rich protein. The interaction between the SH3 domain and proline-rich domain is widely detected.
28-31 We therefore tested whether PRR14′s proline-rich sequence interacts with the SH3 domain of GRB2. We generated glutathione S-transferase (GST)-fusion proteins of full-length, N-terminal SH3, middle part SH2 or C-terminal SH3 of GRB2 (Figure 6a ). The GST pull-down assay revealed a binding of PRR14 to full-length and both SH3 domains, albeit a significant weaker binding of the N-terminal SH3 domain (Figure 6c ). These data were confirmed by co-immunoprecipitation (co-IP; Figures 6d and e) . We also probed which domain of PRR14 binds to GRB2 by generating four fragments of PRR14 peptides as shown in Figure 4b . The results from both GST pull-down (Figure 6f ) and co-IP experiments (Figure 6g ) revealed that PRR14-2 peptide, which contains the proline-rich domain, binds specifically to GRB2. The binding of C terminal of PRR14 (PRR14-4) to GRB2 was also detected in GST pull-down but not in Co-IP experiment, suggesting a nonspecific binding in GST pull-down analysis. 32 Immunofluorescence staining showed the possibility of the two proteins interacting with each other spatially and temporally (S2 B).
We next asked whether the binding of PRR14 to GRB2 mediated its stimulation of Akt/mTOR activity. Indeed, in cells transfected with siRNA to decrease GRB2 expression, PRR14-mediated activation of the Akt/mTOR signaling pathway was significantly compromised (Figure 6h ). The importance of this proline-rich domain-mediated, GRB2 binding was underscored by the observation that the proline-rich domain of PRR14 alone was sufficient to activate Akt/mTOR activity (Figure 6i ). The role of GRB2 in mediating the effect of PRR14 was further confirmed by examining cell proliferation. Remarkably, growth curve ( Figure 6j ) and colony formation assay (Figure 6k) showed that the prolinerich domain alone is adequate to increase cell proliferation and colony formation. The establishment of different cell lines was confirmed by immunofluorescence staining (Supplementary Figure 2C) . Altogether, the data support a critical role of the proline-rich domain-mediated GRB2-binding in promoting PI3K/ Akt/mTOR pathway activity and subsequent cell proliferation.
Characterization of PRR14 mutants derived from cancer patients In addition to overexpression, the TCGA database also revealed rare mutations of the PRR14 gene. We compared the mutants with wild-type PRR14 for their ability to bind to GRB2. Remarkably, two mutants (Table 1) had a binding affinity considerably higher than wild-type PRR14 (Figures 7a and b) . As a consequence to this increased GRB2-binding, these two PRR14 mutants displayed a significantly greater potential of enhancing Ras (Figures 7c and d) and AKT activity (Figures 7e and f) than the wild-type counterpart. Growth curve and colony formation assays were performed to assess these two PRR14 mutants for their biological activity. At a comparable expression level (Figure 7g ), these two mutants induced a greater increase in cell proliferation (Figure 7h ) and colony formation (Figure 7i ) than wild-type PRR14, indicating an augmented ability of these two PRR14 mutants in promoting cancer formation.
PRR14 promotes the xenograft tumor growth
To confirm the effect of PRR14 on lung cancer cell tumorigenicity in vivo, we performed mouse xenograft experiments. H1299 cells stably expressing Flag-PRR14 or empty vector were subcutaneously implanted into either side of nude mice. Quantification of the tumor weights revealed a significantly larger tumor mass from PRR14-overexpressing cell line than the control cells (Figures 8a and b) . The tumor-promoting activity of PRR14 was validated by a complementary knockdown experiment. The result showed that as little as 10% decrease of PRR14 expression by short hairpin RNA (Figure 8c ) reduced significant tumor formation in mice (Figures 8d and e) . Consistent with the in vitro data, the proline-rich domain of PRR14 itself is sufficient to promote tumor formation in mice (Figures 8f and g ).
We also tested the tumorigenicity of the two PRR14 mutants that exhibited an enhanced ability of stimulating cell proliferation. H1299 M1 (Figure 8h ) or H1299 M2 (Figure 8j ) cells, together with PRR14 activates the PI3K pathway in lung cancer M Yang et al wild-type PRR14-expressing H1299 cells, were subcutaneously injected into nude mice to induce tumor formation. Tumor xenografts were weighed and statistically analyzed (Figures 8i and  k) . In agreement with the in vitro data, both PRR14 mutants showed greater tumorigenicity than wild-type PRR14.
DISCUSSION
An elevated activity of the PI3K/AKT/mTOR pathway is a common driving force of lung tumorigenesis. Mutations, dysregulation and epigenetic alterations at various points in the cascade have been reported to contribute to the stimulation of this oncogenic pathway. 33 We demonstrate PRR14, which is upregulated in lung cancer, as a novel activator of the PI3K/AKT/mTOR pathway. Through in vitro and in vivo PRR14 gain-of-function and loss-offunction studies, we confirmed that PRR14 indeed acts as an oncogene in lung cancer.
The PRR14 gene encodes a member of the proline-rich protein family, which contains one proline-rich region flanked by N-and C-terminal nuclear localization signal. 34 The proline-rich region is frequently involved in signaling events through binding with various domains, SH3 domain in particular. [28] [29] [30] [31] Here, we showed that PRR14 is able to directly bind with GRB2 and activate its downstream signal pathway (Figures 4c-h) . Moreover, the binding is mediated by the interaction between PRR14′s proline-rich region and both SH3 domains of GRB2. The importance of the proline-rich domain-mediated binding is highlighted by the findings that the PRR14 proline-rich peptide alone is sufficient to activate the PI3K pathway and to promote cell proliferation in vitro and tumorigenesis in vivo. Of interest is that we also identified two PRR14 mutations from cancer patients, one in the proline-rich region and the other at PRR14′s C terminal. These two mutations enhance PRR14's ability to interact with GRB2, and consequently further stimulate its activity. Although it is unclear why the mutations at such distinct sites caused a similar increase in GRB2-binding, the data suggest that the conformation of the PRR14 protein is very critical for its interaction with GRB2. Further structural studies will be necessary to address this possibility.
SH3 domains are noncatalytic peptide motifs found in many intracellular signaling proteins, including PI3K, 35 Ras GTPase (guanosine triphosphatase)-activating protein 36 and Src-like tyrosine kinases 37 and GRB2. 38, 39 Together with SH2, it mediates Figure 6 . PRR14 interacts with GRB2 to activate the PI3K/Akt/mTOR signaling pathway. Schematic diagram of the domain structures of GRB2 (a) and PRR14 (b) as well as the protein fragments used in this study. A direct interaction between PRR14 and full-length GRB2 or its fragments was shown by GST pull-down (c). Similarly, the direct interaction between GRB2 and PRR14 fragments was shown in f. Co-immunoprecipitation of exogenous PRR14 and GRB2 as well as their fragments in HEK293 cells was shown in (d, e, g). (h) siRNA sequences targeting different sites of GRB2 were co-transfected with either PRR14-coding plasmid or its empty vector into H1299 cells, and 48 h later cells were harvested for western blotting (WB). (i) green fluorescent protein (GFP)-tagged PRR14 fragments 1-4 were transiently transfected into H1299 cells, and cells were harvested for WB 24 h later. (j) H1299 cell lines overexpressing GFP-tagged PRR14 fragments 1-4 were established, and their proliferation rate and tumorigenesis were shown by growth curve (j) and colony formation assay (k).
PRR14 activates the PI3K pathway in lung cancerprotein-protein interaction and regulates signal transduction. The GRB2 protein is composed of a SH2 domain flanked by N-and C-terminal SH3 domains. Co-immunoprecipitation experiment showed that both SH3 domains bind to PRR14 with a comparable affinity (Figure 4e ), whereas GST pull-down assay indicated that the C-terminal SH3 domain has a much stronger binding affinity (Figures 4c) . The data suggest a potential involvement of posttranslational modifications in regulating the interaction between the SH3 domains of GRB2 and PRR14. Nevertheless, our data indicate that, through its proline-rich domain-mediated binding to GRB2, PRR14 stimulates the activity of the PI3K/AKT/mTOR pathway promoting lung carcinogenesis.
MATERIALS AND METHODS
Cell culture, transfection and stable cell line establishment H1299, A549 and HEK293T cells were maintained using standard conditions. DNA transfection was carried out using Lipofectamine 2000 (Invitrogen, Life Technologies, Carlsbad, CA, USA). siRNA (SASI_Hs01_00196781, SASI_Hs01_00196782 and SASI_Hs01_00196783, Sigma, St Louis, MO, USA) transfection was mediated by Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, Life Technologies).
Retroviral production and infection were performed following the protocol from Clontech. Cells were allowed to recover for 24 h before selection with hygromycin for 1 week. Cells transduced with the empty vector were also established and used as control cell lines.
Lentivirus production and infection were performed following the protocol from Addgene. After 24-h recovery, cells were treated with puromycin for 1 week. Plasmids complementary (cDNA) encoding full-length human PRR14 and GRB2 was purchased from DF/HCC DNA Resource Core (Boston, MA, USA) and cloned into pQCXIH (Clontech) and pEGFP-N1 (Clontech) with the Gateway Cloning system (Invitrogen, Life Technologies). For deletion mutation, pEGFP-N1 (Clontech) and pGEX-4T-2 (Sigma) were used and the full-length plasmid was used as template for PCR.
Site-directed mutation was introduced by the Q5 Site-Directed Mutagenesis Kit (NEB, Ipswich, MA, USA). All plasmids were sequenced to confirm the insertion. For Ras pull-down activation assay, plasmid Raf-1 GST RBD 1-149 (#13338, Addgene) was purchased.
RNA preparation, reverse transcription and qPCR Total RNA was extracted using the standard TRIzol method (Life Technologies) and used for the first-strand complementary DNA synthesis with the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Real-time PCR was performed with SYBR Green JumpStart Taq ReadyMix (Sigma) using the StepOnePlus Real-Time PCR System (Bio-Rad). All reactions were run in duplicate. After vortexing, 10 -μl aliquots of the mixture were pipetted into each well of a 96-well thin-wall PCR plate (Bio-Rad). PCRs consisted of a denaturing cycle at 94°C for 2 min, followed by 40 cycles of 15 s at 94°C and 1 min at 60°C. Relative mRNA amounts of target genes were calculated after normalization to an endogenous reference gene (18 s) and relative to the negative control with the arithmetic formula 2 − ΔΔCt.
Flow cytometry analysis and protein synthesis assay Cells were trypsinized, harvested by centrifugation (500 g, 5 min), washed in 4°C phosphate-buffered saline once and gently resuspended in 1 ml hypotonic fluorochrome solution (propidium iodide 50 μg/ml in 0.1% sodium citrate, 10 mM NaCl, 0.3% NP40 plus 25 mg/ml RNase) in polypropylene tubes, followed by incubation in 37°C for 30min. The tubes were placed at 4°C in darkness for flow cytometric analysis.
For protein synthesis assay, cells were treated with or without 50 μg/ml cycloheximide (#2112, Cell Signaling, Danvers, MA, USA) for 30 min, and the Click-iT HPG Alexa Fluor 488 protein synthesis assay kit (C10428, ThermoFisher, Carlsbad, CA, USA) was employed for the visualization of newly synthesized proteins according to the manufacturer's instructions.
Immunohistochemistry, western blotting, GST pull-down assay, immunoprecipitation and Ras pull-down activation assay For western blot analysis, cells were lysed in NP40 supplemented with phosphatase and protease inhibitors. Western blot analysis was performed using standard procedures. For immunohistochemistry, cells were fixed in paraformaldehyde, and blocked with 1% bovine serum albumin/1% Triton X-100/1 × phosphate-buffered saline. The GST pull-down and Co-IP was performed in HEK293T cells. For Ras pull-down activation assay, either H1299 cell lines or transfected H1299 cells were used 48h after transfection, cells were harvested and lysed in RIPA buffer and incubated with purified GST beads (#20211, Life Technology) or flag beads (Anti-FLAG M2 Magnetic Beads, Sigma), following the protocol. 
Statistical analysis
The data are presented as mean ± s.d. Two-tailed Student's t-test was used to determine the significance of the difference between two groups. If not indicated otherwise, the criterion for significance was set at Po0.05 (Prism 6, GraphPad Software, La Jolla, CA, USA).
Differential expression analysis and cohorts
Gene copy number information was taken from UCSC Cancer Genome Browser (https://genome-cancer.ucsc.edu/) for:
• TCGA Lung cancer (LUNG) gistic2_tresholded (983 cases) • TCGA Lung adenocarcinoma (LUAD) gistic2_thresholded (493 cases)
The PRR14 expression level in cancer and control samples was generated with UCSC Cancer Genome Browser (https://genome-cancer. ucsc.edu/) using: The overall survival with follow-up threshold of 5 year was performed using Kaplan-Meier plotter. The expression level cutoff was auto-selected for 218714_at probe. 40 The differential expression analysis within LUAD and LUSC samples was performed on TCGA data using Gitools (http://gitools.org/home). 18 The workflow of an analysis is presented in Supplementary Figure 2 .
The molecular concept-based analysis of over-represented pathways was performed with ConsensusPathDB 19 defining the significance level at 0.001 and minimum of four genes represented in the pathway.
ABBREVIATIONS
Co-IP, Co-immunoprecipitation; DE, Differentially expressed; GRB2, Growth factor receptor-bound protein 2; LUAD, Lung adenocarcinoma; LUSC, Lung Two-tailed Student's t-test was employed to determine the significance of the difference between two groups (b, e, g, i, k). Totally two short hairpin RNAs targeting two different sites of PRR14 were employed to establish H1299 PRR14-deficient cell line, and their efficiency was determined by RT-qPCR. The PRR14 mRNA level was presented as the mean ± s.d. (n = 3). Two-tailed Student's t-test was employed to determine the significance of the difference between two groups (c).
